skip to main content
Deft Research Logo

Blog

Medicare Reimbursement Turmoil

by Brandon Dunk   Medicare Advantage carriers are counting down to April 3rd, and Deft Research is watching with them. April 3, 2023, is the date that CMS will publish its final rate announcement. These rates have already been previewed in the 2024 Medicare Advantage Prescription Drug (MAPD) Advance Notice,...
Read More

Navigating Medicare Disruption

In August of this year, the U.S. Congress passed the Inflation Reduction Act, which promises to lower costs and improve outcomes for American seniors. Beginning in 2026, the Secretary of the Department of Health and Human Services (HHS) will choose a selection from the most expensive Part D drugs each year to come under negotiated price restrictions. Other changes are pending...
Read More

Positive Prospects for ICHRAs

The basis for interest in ICHRAs is clear. Deft Research’s Employer/Employee Group Insurance Study reports that for 46% of employers' payroll deductions increased 6% or more in 2022...
Read More

A Better Way to Explain Your CAHPS/QRS Scores

Identifying the drivers of CAHPS/QRS scores is paramount to long-term financial performance. The customer experience rating moves up or down with overall ratings...
Read More

MA’s Growth and MedSupp’s Contribution

From 2021 to 2022, Medicare Advantage enrollment grew 9% and the program now accounts for 48% of those on Medicare.  Switching from Medsupp to MA has been steady...
Read More

The Challenge of Ad and Message Testing

Creating the most effective marketing campaign is a challenge. In this article we provide several ideas about how imagery, headline, ad copy, and calls-to-action can be measured for their impact on consumers...
Read More
< Previous Next >

Let's Chat

To purchase a study, discuss custom research options, or simply learn more, please share your contact info and a member of our staff will reach out.

By clicking the submit button, I expressly consent by electronic signature to receive communications via automatic telephone dialing system or by artificial/prerecorded message, email or by text message from Deft Research at the telephone number above (even if my number is currently listed on any state, federal, local or corporate Do Not Call list) including my wireless number if provided, for the purpose of marketing insurance products and services. Carrier message and data rates may apply. I understand that my consent is not required as a condition of purchasing any goods or services and that I may revoke my consent at any time. I also acknowledge that I have read and agree to the Privacy Policy and Terms & Conditions.

Not affiliated with or endorsed by the government or federal Medicare program.